Melanoma Chemoprevention

黑色素瘤化学预防

• 批准号: 6625782
• 负责人: ROBERT P. DELLAVALLE
• 金额: $ 13.61万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-06-01 至 2007-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6625782
• 关键词: antihypercholesterolemic agent; antineoplastics; cancer prevention; cancer risk; clinical research; computer data analysis; human data; melanoma; neoplasm /cancer chemotherapy; neoplasm /cancer pharmacology; outcomes research; patient oriented research; statistics /biometry

DESCRIPTION (provided by applicant): The incidence of cutaneous malignant melanoma is rising faster than any other cancer in the US. 1 in 74 Americans will develop melanoma, more than 45,000 cases will be diagnosed, and more than 7,500 Americans will die from melanoma this year. Effective prevention of melanoma will not only save lives, but will also decrease the estimated one billion dollars spent annually treating melanoma in the US. There is currently no recognized chemoprevention for melanoma. Two large, randomized, placebo-controlled clinical trials, the VA-HIT Study utilizing gemfibrozil, and the AFCAPS Study utilizing lovastatin, have each reported an association of lipid-lowering medication therapy with statistically significant lower melanoma incidence rates. Lovastatin inhibits melanoma cell growth in tissue culture, and mice Jed lovastatin develop lower lung metastases following tail vein injection with mouse B16 melanoma cells. More recently low concentrations of atorvastatin have been reported to specifically induce apoptosis and inhibit migration of human A375 melanoma cells but not cultured melanocytes. To investigate the unconventional hypothesis that lipid-lowering medications might prevent melanoma, a case-control study will be conducted utilizing Veterans Administration (VA) databases to answer the following question: Do persons who have developed cutaneous malignant melanoma have a history of less lipid-lowering medication exposure than persons who are spared the disease? The answer to this question will help determine whether more expensive and labor intensive randomized prospective clinical trials of potentially teratogenic lipid-lowering medications should be initiated in persons at high risk of developing melanoma. Robert Dellavalle, MD, Ph.D., is an Assistant Professor of Dermatology at the University of Colorado Health Sciences Center and a staff dermatologist at the Denver VA medical center He is committed to a career in academic dermatology and public health. His current career goals are completing a Masters of Science in Public Health and becoming an independent researcher in skin cancer prevention and control.

描述(申请人提供)：皮肤恶性肿瘤的发病率 在美国，黑色素瘤的增长速度比其他任何癌症都要快。每74个美国人中就有1个 将会发展成黑色素瘤，将有超过45,000个病例被诊断，超过 今年将有7500名美国人死于黑色素瘤。有效预防 黑色素瘤不仅会挽救生命，而且还会降低估计的死亡率 在美国，每年花费在治疗黑色素瘤上的资金高达10亿美元。 目前还没有公认的黑色素瘤的化学预防方法。两个大的， 随机、安慰剂对照临床试验，VA-HIT研究利用 吉非罗齐和利用洛伐他汀的AFCAPS研究各自报告了一个 降脂药物治疗与统计学的关系 显著降低黑色素瘤发病率。洛伐他汀抑制黑色素瘤细胞 在组织培养中生长，小鼠出现洛伐他汀下肺 尾静脉注射小鼠B16黑色素瘤细胞后的转移。更多 最近，低浓度的阿托伐他汀被报道为 诱导人A375黑色素瘤细胞凋亡并抑制其迁移 培养的黑素细胞。为了调查非常规假设 一项病例对照研究表明，降脂药物可能会预防黑色素瘤 利用退伍军人管理局(VA)数据库进行 以下问题：患上皮肤恶性疾病的人 黑色素瘤有较少的降脂药物暴露史 那些幸免于这种疾病的人？这个问题的答案会有所帮助 确定更昂贵和劳动密集型的随机预期 潜在致畸降脂药物的临床试验应该 在患黑色素瘤的高危人群中启动。 罗伯特·德拉瓦莱，医学博士，皮肤科助理教授 科罗拉多大学健康科学中心的一名皮肤科医生 丹佛弗吉尼亚州医学中心，他致力于皮肤科学术生涯 和公共卫生。他目前的职业目标是完成 公共卫生科学和成为皮肤癌的独立研究人员 防控。